Clinical Trials
207
14 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1955
Active, not recruiting
7
3.4%
Completed
133
64.3%
Enrolling By Invitation
2
1.0%
Not yet recruiting
5
2.4%
Recruiting
17
8.2%
Terminated
30
14.5%
Unknown
1
0.5%
Withdrawn
12
5.8%
No approval data available
- A Nature study led by Mount Sinai researchers identifies Sst-Chodl neurons in the cerebral cortex as an active driver of sleep rather than a passive follower of deep brain centers. - Sst-Chodl neurons make up roughly 0.2% of cortical neurons but send long-range signals capable of synchronizing activity across large areas of the brain. - Activating these neurons slowed and synchronized neocortical electrical activity and was sufficient to make mice fall asleep more readily and sleep longer. - The neurons are conserved across hundreds of millions of years of evolution, from amphibians and reptiles to humans, suggesting a fundamental function.
- Geneticist Nir Barzilai argues that targeting the biology of aging could extend "health span," the healthy years of life, rather than treating individual diseases one at a time. - Barzilai co-leads the SuperAgers Initiative, which aims to recruit 10,000 people over age 95 and their families to identify longevity genes linked to cholesterol and lipid metabolism. - He designed a clinical trial testing whether the diabetes drug metformin can delay age-related diseases such as cardiovascular disease and cancer, a design adaptable to GLP-1 medications. - Barzilai favors the term "geroscience" over "longevity," emphasizing the mechanism of aging biology rather than the outcome, to distinguish rigorous science from hype.
- Researchers found that "super movers" — people over 80 with exceptionally fast walking speeds — are approximately 50% less likely to develop cognitive decline compared to slower peers of the same age. - The study, published in Neurology, analyzed nearly 4,000 older adults and found the fastest 9% preserved hippocampal volume and showed resilience against cognitive symptoms despite brain plaques and tangles. - Muscle health plays a key role, as contracting muscles release signaling molecules like BDNF that support brain cell growth, memory, and cognitive function. - Experts emphasize that lifestyle habits matter, and brisk walking at around 3 miles per hour for at least 30 minutes daily may help put individuals on a path to becoming super movers.
- Albert Einstein College of Medicine has launched BIO-VITAL, a new initiative funded by the Ofer Family Foundation to help biotech and pharmaceutical companies advance therapies targeting the biology of aging. - The program offers industry partners access to more than 30 assays and services across three integrated research cores spanning cellular aging, preclinical models, and human longevity multi-omics. - BIO-VITAL is housed within Einstein's Institute for Geroscience, which has pioneered aging research for over 30 years, with the goal of improving healthspan and delaying age-related diseases including cancer, diabetes, and cardiovascular disease. - The initiative connects discoveries across molecular, cellular, preclinical, and human population scales, providing translational insights designed to accelerate geroscience programs toward the clinic.
- Researchers in Argentina reported that four of five hantavirus patients survived after receiving tocilizumab, a rheumatoid arthritis drug, compared to five deaths among patients who received only standard care. - The study represents the first use of tocilizumab in a compassionate use trial for hantavirus pulmonary syndrome, targeting the IL-6 inflammatory pathway that contributes to lung failure. - Multiple research teams are developing antibody treatments and vaccines for hantavirus, but limited funding and the virus's rarity have hindered progress despite mortality rates reaching 35-40%. - Recent cruise ship outbreak that killed three passengers has renewed attention to hantavirus research, with scientists hoping for increased investment in treatment development.
- Researchers at Albert Einstein College of Medicine have developed a new CAR-T cell manufacturing approach using a multi-cytokine fusion protein scaffold that dramatically extends the cells' therapeutic lifespan and effectiveness. - The innovative method generates CAR-T cells with over 50% T memory stem cells compared to less than 5% with conventional manufacturing, providing enhanced self-renewal capacity and sustained disease-fighting ability. - In mouse models, the new approach demonstrated superior performance against both blood cancers and HIV infection, with enhanced recall responses preventing tumor recurrence and more effective viral suppression. - The breakthrough could significantly reduce cancer relapse rates and advance HIV treatment toward a functional cure by maintaining long-term viral control after stopping antiretroviral therapy.
- More than a dozen former FDA commissioners published a warning in the New England Journal of Medicine opposing proposed changes to vaccine approval standards by current FDA biologics chief Vinay Prasad. - The former officials argue that rejecting immunobridging studies would undermine the regulatory framework for vaccines that require frequent updates, particularly COVID-19 and influenza vaccines. - Former CDC director Rochelle Walensky and colleagues published analysis in JAMA showing that delaying hepatitis B birth dose vaccination could increase perinatal infections by 8% to 76%. - These warnings coincide with the CDC's Advisory Committee on Immunization Practices meeting where changes to hepatitis B vaccination policy are under debate.
- Eikon Therapeutics will present new Phase 2 data on EIK1001, a novel TLR7/8 co-agonist, in combination with pembrolizumab and chemotherapy for first-line treatment of stage 4 non-small cell lung cancer at ESMO 2025. - The TeLuRide-005 study results have been reviewed in a successful end-of-Phase-2 meeting with the FDA, supporting advancement into a registration-enabling Phase 2/3 trial. - EIK1001 is designed to stimulate broad immune activation through TLR7/8 co-activation to enhance T-cell recognition and tumor killing in advanced NSCLC patients. - The company is also advancing EIK1001 in a seamless Phase 2/3 trial for advanced melanoma, demonstrating momentum across its oncology pipeline.
- A comprehensive 17-year study of 2,335 women found HPV vaccines achieved up to 98.4% reduction in targeted infections among vaccinated participants in real-world settings. - Unvaccinated women also experienced significant protection through herd immunity, with infection rates dropping by up to 75.8% for vaccine-targeted HPV types. - The research confirms HPV vaccines remain highly effective even among high-risk populations, with 79% of participants having multiple sexual partners and 51% having prior sexually transmitted infections. - Study findings support the potential for global cervical cancer elimination, as vaccination rates increased from 0% to 82% over the study period.
- Vascarta Inc. announced that the FDA has granted Orphan Drug Designation to Vasceptor (VAS-101), a patented topical curcumin formulation for treating Sickle Cell Disease. - The designation provides seven years of market exclusivity upon approval, tax credits for clinical trials, and exemption from certain FDA fees for this rare disease therapy. - Preclinical results demonstrate that VAS-101's novel approach targets red blood cell instability, neuro-inflammation and vascular inflammation to reduce pain and improve therapeutic efficacy. - The drug is currently in Phase 1 clinical trials at the Foundation for Sickle Cell Disease Research in Hollywood, Florida, using patented transdermal technology to overcome curcumin's poor oral bioavailability.
